These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34399998)

  • 41. ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
    Chan OSH; Lam KC; Li JYC; Choi FPT; Wong CYH; Chang ATY; Mo FKF; Wang K; Yeung RMW; Mok TSK
    Lung Cancer; 2020 Apr; 142():41-46. PubMed ID: 32088604
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide.
    La Vecchia M; Fazio I; Borsellino N; Lo Casto A; Galanti D
    Tumori; 2023 Aug; 109(4):413-417. PubMed ID: 36358013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
    Kwan EM; Spain L; Anton A; Gan CL; Garrett L; Chang D; Liow E; Bennett C; Zheng T; Yu J; Dai C; Du P; Jia S; Fettke H; Abou-Seif C; Kothari G; Shaw M; Parente P; Pezaro C; Tran B; Siva S; Azad AA
    Eur Urol; 2022 Mar; 81(3):253-262. PubMed ID: 34493414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.
    Deek MP; Taparra K; Phillips R; Velho PI; Gao RW; Deville C; Song DY; Greco S; Carducci M; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Tran PT; Stish BJ
    Eur Urol Oncol; 2021 Jun; 4(3):447-455. PubMed ID: 32536574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease?
    Aquilano M; Loi M; Visani L; Livi L; Nuyttens JJ
    Acta Oncol; 2023 Mar; 62(3):298-304. PubMed ID: 36905644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.
    Rans K; Joniau S; Berghen C; Goffin K; Dumez H; Haustermans K; De Meerleer G
    Eur Urol Oncol; 2024 Dec; 7(6):1441-1450. PubMed ID: 38664137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
    Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
    Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
    Raj RK; Upadhyay R; Wang SJ; Singer EA; Dason S
    Curr Oncol; 2023 Dec; 30(12):10283-10298. PubMed ID: 38132383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.
    Correa RJM; Ahmad B; Warner A; Johnson C; MacKenzie MJ; Pautler SE; Bauman GS; Rodrigues GB; Louie AV
    Radiat Oncol; 2018 Mar; 13(1):47. PubMed ID: 29558966
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
    Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
    Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis.
    Chan OSH; Lee VHF; Mok TSK; Mo F; Chang ATY; Yeung RMW
    Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):568-575. PubMed ID: 28499791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic breast cancer: Treatment indication matters.
    Tan H; Cheung P; Louie AV; Myrehaug S; Niglas M; Atenafu EG; Chu W; Chung HT; Poon I; Sahgal A; Soliman H
    Radiother Oncol; 2021 Aug; 161():159-165. PubMed ID: 34119585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.
    Verma J; Jonasch E; Allen PK; Weinberg JS; Tannir N; Chang EL; Mahajan A
    Am J Clin Oncol; 2013 Dec; 36(6):620-4. PubMed ID: 22892430
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SBRT for oligoprogressive oncogene addicted NSCLC.
    Basler L; Kroeze SG; Guckenberger M
    Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
    Franzese C; Perrino M; Marzo MA; Badalamenti M; Baldaccini D; D'Agostino G; Marini B; De Vincenzo F; Zucali PA; Scorsetti M
    Clin Exp Metastasis; 2022 Jun; 39(3):449-457. PubMed ID: 35190933
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study.
    Onal C; Guler OC; Hurmuz P; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
    Strahlenther Onkol; 2022 Oct; 198(10):940-948. PubMed ID: 35695908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014.
    Stenman M; Sinclair G; Paavola P; Wersäll P; Harmenberg U; Lindskog M
    Radiother Oncol; 2018 Jun; 127(3):501-506. PubMed ID: 29754859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
    Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
    Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.